BioCardia (NASDAQ:BCDA – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company’s 50-day moving average price is $0.94 and its two-hundred day moving average price is $1.11. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. According to data from MarketBeat, BioCardia presently has a consensus rating of “Reduce” and an average price target of $25.00. BioCardia Company Profile(Get Free Report)BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease.